Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 8/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.31 |
| ▸ | TUBB | P07437 | 1/20 | 0.31 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.31 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.31 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.31 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.31 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.31 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.31 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.31 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.31 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.31 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22980423 | 0.80 | KAT2B (0.36) | HDAC8HDAC1HDAC6HDAC3HDAC2 | |
| SCHEMBL4149156 | 0.80 | GPR119 (0.40) | NR1H2HDAC1HDAC6NR1H3SETD7 | |
| SCHEMBL17242214 | 0.79 | NR1H2 (0.38) | NR1H2HDAC1HDAC6NR1H3SETD7 | |
| SCHEMBL16041668 | 0.79 | NR1H2 (0.48) | NR1H2HDAC1HDAC6NR1H3SETD7 | |
| SCHEMBL23727382 | 0.77 | NR1H2 (0.36) | NR1H2HDAC1HDAC6NR1H3KDM1A | |
| SCHEMBL15878939 | 0.75 | CHKA (0.47) | HDAC6 | |
| SCHEMBL22980685 | 0.75 | HDAC1 (0.47) | HDAC8NR1H2HDAC1 | |
| SCHEMBL29405550 | 0.75 | HDAC1 (0.47) | HDAC8NR1H2HDAC1 | |
| SCHEMBL30811770 | 0.74 | NR1H2 (0.39) | HDAC8NR1H2NR1H3 | |
| SCHEMBL25976960 | 0.74 | NR1H2 (0.39) | HDAC8NR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250080-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LTD (GB) | 2023-08-10 | — | — | US | disclosed |
| US-11613527-B2 | Enzyme inhibitors | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2023-03-28 | — | — | US | disclosed |
| EP-4010333-A1 | PLASMA KALLIKREIN INHIBITORS | Kalvista Pharmaceuticals Limited (GB) | 2022-06-15 | — | — | EP | disclosed |
| US-20220048894-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2022-02-17 | — | — | US | disclosed |
| WO-2021028649-A1 | PLASMA KALLIKREIN INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2021-02-18 | — | — | WO | disclosed |
| WO-2021028645-A1 | PLASMA KALLIKREIN INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2021-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250080-A1 | ENZYME INHIBITORS | SERPINB1, KLKB1, SERPINE1 | HDAC8 1183/4885NR1H2 794/4885HDAC1 286/4885 |
| US-11613527-B2 | Enzyme inhibitors | SERPINB1, KLKB1, SERPINE1 | HDAC8 1183/4885NR1H2 794/4885HDAC1 286/4885 |
| US-20220048894-A1 | ENZYME INHIBITORS | SERPINB1, KLKB1, SERPINE1 | HDAC8 1183/4885NR1H2 794/4885HDAC1 286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.